DiaMedica Therapeutics Inc. Revenue 2018–2018
DiaMedica Therapeutics Inc. annual/quarterly revenue history and growth rate from 2018 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- DiaMedica Therapeutics Inc. revenue for the quarter ending September 30, 2018 was 500000.
- DiaMedica Therapeutics Inc. annual revenue for 2018 was 500000.
DiaMedica Therapeutics Inc. (DMAC) — Frequently Asked Questions
DiaMedica Therapeutics Inc. (DMAC) is a publicly traded US company. It has a market capitalization of $64M. In fiscal 2018 it reported revenue of $500,000 and net income of -$6M. Explore DMAC's stock price, financial statements, earnings history, margins and key ratios below.
What is DiaMedica Therapeutics Inc.'s market cap?
DiaMedica Therapeutics Inc. (DMAC) has a market capitalization of $64M.
What is the DMAC stock price?
DMAC trades at $5.33 (-1.66% on the day).
How much revenue does DiaMedica Therapeutics Inc. make?
DiaMedica Therapeutics Inc. reported revenue of $500,000 in fiscal 2018.
Is DMAC profitable?
In fiscal 2018, DiaMedica Therapeutics Inc. reported net income of -$6M.